MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$182K
Net Income
-$14,713K
Net Profit Margin
-8084.07%
EPS
-$0.49
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Product revenue, net
182
206
98
120
Restructuring costs
-
-
194
0
Cost of goods sold
22
283
11
107
Research and development
3,164
2,955
8,740
10,256
Selling, general and administrative
7,189
7,191
5,381
5,609
Total operating expenses
10,375
10,429
14,326
15,972
Loss from operations
-10,193
-10,223
-14,228
-15,852
Interest expense
4,257
4,198
4,373
4,222
Interest income
131
211
236
230
Other (income) expense, net
-394
1,519
-12,546
657
Net loss
-14,713
-12,691
-30,911
-19,187
Basic EPS
-0.49
-0.54
-2.18
-2.45
Diluted EPS
-0.49
-0.54
-2.18
-2.45
Basic Average Shares
30,300,000
23,571,000
14,196,000
7,843,000
Diluted Average Shares
30,300,000
23,571,000
14,196,000
7,843,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$14,713K
(23.32%↑ Y/Y)
Interest income
$131K
(-43.04%↓ Y/Y)
Loss from operations
-$10,193K
(35.70%↑ Y/Y)
Interest expense
$4,257K
(0.83%↑ Y/Y)
Other (income)
expense, net
-$394K
(-159.97%↓ Y/Y)
Product revenue, net
$182K
(51.67%↑ Y/Y)
Total operating
expenses
$10,375K
(-35.04%↓ Y/Y)
Selling, general and
administrative
$7,189K
(28.17%↑ Y/Y)
Research and development
$3,164K
(-69.15%↓ Y/Y)
Cost of goods sold
$22K
(-79.44%↓ Y/Y)
Buy us a coffee
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)